Thermo Fisher Scientific Opens New Singapore Location
On Nov. 18, 2015 Thermo Fisher Scientific Inc., a life sciences research company, announced the opening of their new GMP clinical services facility in Singapore. This new facility is meant to help meet the growing demand for clinical supply services in the region.
According to a press release from the company, Thermo Fisher Scientific Inc. opened its first clinical services facility in Singapore in 2001. The new facility will be located on Toh Guan Road, Jurong East and is nearly 70,000 ft2-60% larger than the previous site. The new site will provide pharmaceutical and biotech companies with clinical supplies including GMP storage, local labeling, secondary packaging, comparator sourcing, handling, and distribution of ambient and cold chain supplies.
Leon Wyszkowski, Thermo Fisher’s vice-president of Clinical Services for North America and facility network, says Singapore is the company’s fastest growing market and contributor to their growth. According to the company, clinical trial studies conducted in emerging Asian markets have increased in the past ten years, as a result of lower study costs and large patient populations.
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
